Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 13Phase 1 13Phase NA 2Phase EARLY_PHASE1 2Phase 3 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 13Squamous Cell Carcinoma of Head and Neck 12Prostatic Neoplasms 11Neoplasms 11Breast Neoplasms 9Ovarian Neoplasms 8Lung Neoplasms 8Leukemia, Myeloid, Acute 8Recurrence 7Myasthenia Gravis 7Head and Neck Neoplasms 7Stomach Neoplasms 6Colorectal Neoplasms 6Pancreatic Neoplasms 5Oropharyngeal Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Fatigue 5Urinary Bladder Neoplasms 4Mouth Neoplasms 4Melanoma 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Cholangiocarcinoma 4Rectal Neoplasms 3Peritoneal Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Glioblastoma 3

Interventions

venetoclax 1cedazuridine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia, Myelomonocytic, Chronic × 90 days × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡